Diabetes complications

Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm

Diabetes CarePublished Retrospective cohort study

Authors' conclusion

Relatively simple logistic regression models using nine readily available clinical variables can be used to rank order patients for onset of diabetic eye disease and thereby more efficiently prioritize and target screening for at risk patients.

Study context

Population
Patients from the Kaiser Permanente Northern California Diabetes Registry with no evidence of DR at a baseline DR screening, 2008–2020; 51.9% male, 42.1% White, mean age 60.0 (±13.1) years
Participants
276,794 patients
Exposure
XGBoost machine learning algorithm vs nine-covariate logistic regression model
Outcome
Onset of proliferative DR, diabetic macular edema and referable retinopathy detected through routine screening; model performance by AUC
Methodological detailsprediction model development and internal validation
  • Prediction model development and internal validation

Main finding

As reported in the abstract

AUC for onset of proliferative DR, diabetic macular edema and referable retinopathy
GroupAUC proliferative DRAUC diabetic macular edemaAUC referable retinopathy
XGBoost0.86 (95% CI, 0.86-0.87)0.76 (95% CI, 0.75-0.77)0.78 (95% CI, 0.78-0.79)
Logistic regression0.82 (95% CI, 0.80-0.83)0.73 (95% CI, 0.72-0.74)0.75 (95% CI, 0.75-0.76)

AUC proliferative DR

XGBoost0.86 (95% CI, 0.86-0.87)
Logistic regression0.82 (95% CI, 0.80-0.83)

AUC diabetic macular edema

XGBoost0.76 (95% CI, 0.75-0.77)
Logistic regression0.73 (95% CI, 0.72-0.74)

AUC referable retinopathy

XGBoost0.78 (95% CI, 0.78-0.79)
Logistic regression0.75 (95% CI, 0.75-0.76)

Observational data: associations, not effects.

Original publication

Development and Validation of a Diabetic Retinopathy Risk Stratification Algorithm. Diabetes Care. Published 17 March 2023. doi:10.2337/dc22-1168

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.